Peptide targeted radiotherapy – a promising new approach to cancer therapy.
Treating cancer with radiotherapy means achieving results not possible with conventional therapies. Cancer cells are unable to evade the lethal damage caused by targeted radiation.
Our targeted therapy has been widely validated in clinical studies as well as in routine clinical use in Europe. Learn More
“Precision medicine using targeted radiotherapy has been a game-changer for me. I was diagnosed with cancer a few years ago and traditional treatments were not effective. But with targeted radiotherapy, I have seen significant improvement in my condition.” – John Doe
October 23, 2024 Innovative Approach to Rare Cancer Treatment Attracts Attention from Industry Leaders and Patient Groups Boston — Andarix Pharmaceuticals, a leader in the discovery and development of targeted peptide therapy for rare cancers, announced today that its CEO, Chris Adams will present the two-day conference on outsourcing clinical… Read more: Andarix Pharmaceuticals CEO to Groundbreaking Targeted Peptide Therapy at Clinical Trials Conference
September, 2023 Andarix Pharmaceuticals CEO to Chair Rare Disease Clinical Trials Conference Boston — Andarix Pharmaceuticals, a leader in the discovery and development of targeted peptide therapy for rare cancers announced today that its CEO, Chris Adams will Chair the two days conference on rare diseases. The conference will include… Read more: Andarix Pharmaceuticals CEO to Chair Rare Disease Clinical Trials Conference
July 11, 2023 Conference Highlights Key Features of Successful Clinical Trial Management SOMERVILLE, MA — July 11, 2023 — Andarix Pharmaceuticals, a leader in the discovery and development of targeted peptide therapy for cancer announced today that it will lead a panel discussion composed of industry experts on the key… Read more: Andarix Pharmaceuticals to Lead Panel Discussion at Clinical Trial Conference
Andarix Pharmaceuticals, a leader in the
discovery and development of targeted peptide therapy for cancer announced today that
it has been granted the US trademark for Tozaride by the United States Patent and
Trademark Office.
October 23, 2024 Innovative Approach to Rare Cancer Treatment Attracts Attention from Industry Leaders and Patient Groups Boston — Andarix Pharmaceuticals, a leader in the discovery and development of targeted peptide therapy for rare cancers, announced today that its CEO, Chris Adams will present the two-day conference on outsourcing clinical… Read more: Andarix Pharmaceuticals CEO to Groundbreaking Targeted Peptide Therapy at Clinical Trials Conference
September, 2023 Andarix Pharmaceuticals CEO to Chair Rare Disease Clinical Trials Conference Boston — Andarix Pharmaceuticals, a leader in the discovery and development of targeted peptide therapy for rare cancers announced today that its CEO, Chris Adams will Chair the two days conference on rare diseases. The conference will include… Read more: Andarix Pharmaceuticals CEO to Chair Rare Disease Clinical Trials Conference
July 11, 2023 Conference Highlights Key Features of Successful Clinical Trial Management SOMERVILLE, MA — July 11, 2023 — Andarix Pharmaceuticals, a leader in the discovery and development of targeted peptide therapy for cancer announced today that it will lead a panel discussion composed of industry experts on the key… Read more: Andarix Pharmaceuticals to Lead Panel Discussion at Clinical Trial Conference
November 2, 2022 Personalized and targeted medicine for lung and other cancers SOMERVILLE, MA —November 2, 2022— Andarix Pharmaceuticals, a leader in the discovery and development of targeted peptide therapy for cancer announced today that it will participate on a panel discussion of biotech company formation and management experiences. The… Read more: Andarix Pharmaceuticals to Participate in Life Science Panel of Biotech and MedTech Entrepreneurs at Life Science Summit 22
Andarix Pharmaceuticals, a leader in the discovery and development of targeted peptide therapy for cancer announced today that it has been granted the US trademark for Tozaride by the United States Patent and Trademark Office.